in patients who received tissue plasminogen activator (TPA) for acute stroke (data from the Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register) and control ...
Medpage Today on MSN1mon
Tenecteplase No Longer Off-Label as Stroke LyticA clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated ... Tenecteplase thus officially joins ...
The primary end point was functional independence on discharge. Data were included for 79,550 patients treated with intravenous thrombolysis, of whom 11.9% and 88.1% received tenecteplase and ...
As a result, there is decreased reperfusion after tissue plasmogin activator (tPA)-induced recanalization ... The PROACT II stroke thrombolysis trial (Kase et al., 2001) also found conclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback